It’s likely that Merck’s COVID-19 pill will be authorized in the U.S. this month but it's expected to be restricted to certain high-risk people.
Read More...
It’s likely that Merck’s COVID-19 pill will be authorized in the U.S. this month but it's expected to be restricted to certain high-risk people.
Read More...
The Wall Street giant really likes these dividend stocks — for very good reasons. Read More...
To give you a reference point, the Federal Reserve targets an annual inflation rate of about 2%. The question is whether it's transitory (pushed higher by...
Bargains aren't bargains if there's not much hope for a strong rebound move. Read More...
The metaverse could be one of the biggest emerging product and service trends of 2022, but investors don't have to wait to build an early position in this...
After rocketing higher in 2020 and early 2021, many growth stocks suddenly slammed on the brakes. Three Fool.com contributors think Zynga (NASDAQ: ZNGA)...
Believe it or not, the stock of Amazon (NASDAQ: AMZN) has done basically nothing over the past year and half. Looking underneath the hood, AWS accelerated 39%...
Some people think a market crash is just around the corner; these three stocks are worth scooping up if that occurs. Read More...
It's the premier "picks-and-shovels" supplier for the technologies shaping our future. Read More...
Buying innovators and disruptors at a discount is a smart way to set yourself up for long-term success. Read More...